NASDAQ · Biotechnology · USD

ABVC BioPharma, Inc. (ABVC) Stock Analysis

ABVC BioPharma, Inc. (ABVC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ABVC

$0.96

−$0.04 (−4.00%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ABVC with… →

ABVC Key Statistics

As of Sep 4, 2026

Trading

Open: $1.00
Previous Close: $1.00
Day's Range: 0.90–1.02
52-Week Range: 0.71–3.40
Volume: 142.40K
Beta: 0.61

Valuation

Market Cap: $25.59M
P/E Ratio: unprofitable
EPS (ttm): −0.29

Financials (FY)

Revenue (FY): $0.00−100.00%
Net Income (FY): −$7.91M
Profit margin: 0.00%
Shares Outstanding: 26.65M
1-Year Return: −64.71%

Dividend and dates

Avg Volume: 135.85K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ABVC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−87.86%+261.02%−54.93%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	−54.93%
2025	+261.02%
2024	−49.14%
2023	−81.44%
2022	−81.56%
2021	−33.53%
2020	+16.70%
2019	−87.86%
2018	+0.00%
2017	+0.00%
2016 (partial year)	+0.00%

As of September 4, 2026.

ABVC Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$7.91M	—
2024	$509.59K	−$4.90M	−962.1%
2023	$152.43K	−$7.79M	−5109.3%
2022	$969.78K	−$16.42M	−1693.5%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	$0.00	−$7.15M	−$7.91M	—
2024	$509.59K	$508.83K	−$4.71M	−$4.90M	−962.1%
2023	$152.43K	−$149.61K	−$6.77M	−$7.79M	−5109.3%
2022	$969.78K	$683.37K	−$15.11M	−$16.42M	−1693.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ABVC Valuation vs Biotechnology Median

Median of 656 stocks

Metric	ABVC	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values ABVC BioPharma, Inc. (ABVC) at $25.59M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 16.

The 52-week range on file runs from $0.71 to $3.40. The most recent close on file for ABVC is $0.96, dated September 4, 2026. That is −$0.04 (−4.00%) against the previous close. The latest close sits 35.79% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. Against the prior fiscal year total of $509.59K, that is a change of −100.00%. The same year closed with a net loss of $7.91M. The reported profit margin is 0%. Trailing earnings per share are −0.29.

Across the 4 fiscal years on file, revenue moves from $969.78K in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the price has returned −64.71%. Across 10 years the annualized return works out at −44.72%. The reported beta is 0.61. Annualized volatility over the trailing 10 years is 439.32%.

Growth & Income

The record shows no dividend for ABVC.

Across the complete calendar years on file, 2025 returned +261.02% and 2019 returned −87.86%. Of the 9 complete calendar years on file, 2 finished higher. So far in 2026 the price is −54.93%.

Peer Comparison

ABVC BioPharma, Inc. (ABVC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
ABVC BioPharma, Inc.	ABVC	$25.59M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. ABVC BioPharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About ABVC BioPharma, Inc.

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.

Visit website →